应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01167 加科思-B
已收盘 12-19 16:08:47
1.320
-0.020
-1.49%
最高
1.370
最低
1.260
成交量
80.76万
今开
1.300
昨收
1.340
日振幅
8.21%
总市值
10.42亿
流通市值
10.42亿
总股本
7.89亿
成交额
105.90万
换手率
0.10%
流通股本
7.89亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
加科思-B盘中异动 早盘股价大跌5.22%
市场透视 · 10:27
加科思-B盘中异动 早盘股价大跌5.22%
加科思-B(01167)股价上升6.349%,现价港币$1.34
阿斯达克财经 · 12-18 15:34
加科思-B(01167)股价上升6.349%,现价港币$1.34
加科思-B(01167)上涨5.56%,报1.33元/股
金融界 · 12-18 14:23
加科思-B(01167)上涨5.56%,报1.33元/股
加科思-B盘中异动 早盘大幅上涨7.14%报1.350港元
市场透视 · 12-18 10:04
加科思-B盘中异动 早盘大幅上涨7.14%报1.350港元
加科思-B12月16日主力资金流出66万元 连续3日减仓
市场透视 · 12-16
加科思-B12月16日主力资金流出66万元 连续3日减仓
加科思-B(01167)下跌5.07%,报1.31元/股
金融界 · 12-16
加科思-B(01167)下跌5.07%,报1.31元/股
加科思-B盘中异动 早盘快速上涨6.52%报1.470港元
市场透视 · 12-16
加科思-B盘中异动 早盘快速上涨6.52%报1.470港元
加科思-B12月13日遭主力抛售41万元 环比增加355.56%
市场透视 · 12-13
加科思-B12月13日遭主力抛售41万元 环比增加355.56%
加科思-B(01167)下跌5.59%,报1.35元/股
金融界 · 12-13
加科思-B(01167)下跌5.59%,报1.35元/股
加科思-B盘中异动 早盘股价大跌5.59%报1.350港元
市场透视 · 12-13
加科思-B盘中异动 早盘股价大跌5.59%报1.350港元
加科思-B(01167)股价下跌5.594%,现价港币$1.35
阿斯达克财经 · 12-13
加科思-B(01167)股价下跌5.594%,现价港币$1.35
加科思-B12月10日遭主力抛售25万元 环比增加150.00%
市场透视 · 12-10
加科思-B12月10日遭主力抛售25万元 环比增加150.00%
加科思-B(01167)下跌5.92%,报1.43元/股
金融界 · 12-10
加科思-B(01167)下跌5.92%,报1.43元/股
加科思-B盘中异动 快速下跌5.26%报1.440港元
市场透视 · 12-10
加科思-B盘中异动 快速下跌5.26%报1.440港元
加科思展示BET抑制剂初步临床数据
财中社 · 12-09
加科思展示BET抑制剂初步临床数据
加科思(01167)在66届美国血液学会上展示JAB-8263治疗骨髓纤维化临床的初步数据
金吾财讯 · 12-09
加科思(01167)在66届美国血液学会上展示JAB-8263治疗骨髓纤维化临床的初步数据
加科思(01167.HK)于美国展示治疗骨髓纤维化药物临床数据
阿斯达克财经 · 12-09
加科思(01167.HK)于美国展示治疗骨髓纤维化药物临床数据
加科思-B(01167)在2024年第66届美国血液学会年会上展示了BET抑制剂JAB-8263 治疗骨髓纤维化(MF)临床一期的初步数据
智通财经 · 12-09
加科思-B(01167)在2024年第66届美国血液学会年会上展示了BET抑制剂JAB-8263 治疗骨髓纤维化(MF)临床一期的初步数据
加科思-B盘中异动 股价大涨5.59%
市场透视 · 12-06
加科思-B盘中异动 股价大涨5.59%
加科思-B(01167)下跌5.16%,报1.47元/股
金融界 · 11-29
加科思-B(01167)下跌5.16%,报1.47元/股
公司概况
公司名称:
加科思-B
所属市场:
SEHK
上市日期:
--
主营业务:
加科思药业集团有限公司是一家主要从事临床阶段新药研发的中国投资控股公司。该公司主要负责创新肿瘤疗法的自主发现和开发。公司主要药物开发项目包括JAB-3068及JAB-3312临床阶段的变构SHP2抑制剂。该公司主要在国内市场开展业务。
发行价格:
--
{"stockData":{"symbol":"01167","market":"HK","secType":"STK","nameCN":"加科思-B","latestPrice":1.32,"timestamp":1734595727013,"preClose":1.34,"halted":0,"volume":807600,"delay":0,"floatShares":789419880,"shares":789419880,"eps":-0.49846426,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.02,"latestTime":"12-19 16:08:47","open":1.3,"high":1.37,"low":1.26,"amount":1059048,"amplitude":0.08209,"askPrice":1.32,"askSize":21300,"bidPrice":1.31,"bidSize":1500,"shortable":0,"etf":0,"ttmEps":-0.5000861999813377,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"listingDate":1608480000000,"adjPreClose":1.34,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":0.515294,"lotSize":300,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01167/wiki","defaultTab":"wiki","newsList":[{"id":"2492196939","title":"加科思-B盘中异动 早盘股价大跌5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492196939","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492196939?lang=zh_cn&edition=full","pubTime":"2024-12-19 10:27","pubTimestamp":1734575223,"startTime":"0","endTime":"0","summary":"2024年12月19日早盘10时27分,加科思-B股票出现波动,股价快速下跌5.22%。截至发稿,该股报1.270港元/股,成交量8.82万股,换手率0.01%,振幅2.99%。加科思-B股票所在的生物技术行业中,整体跌幅为1.13%。其相关个股中,思路迪医药股份、来凯医药-B、乐普生物-B涨幅较大,振幅较大的相关个股有来凯医药-B、晶泰控股-P、永泰生物-B,振幅分别为18.50%、13.59%、12.28%。公司主要药物开发项目包括JAB-3068及JAB-3312临床阶段的变构SHP2抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121910270395ea657d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121910270395ea657d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01167","BK1574"],"gpt_icon":0},{"id":"2492849976","title":"加科思-B(01167)股价上升6.349%,现价港币$1.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2492849976","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492849976?lang=zh_cn&edition=full","pubTime":"2024-12-18 15:34","pubTimestamp":1734507240,"startTime":"0","endTime":"0","summary":"[上升股]加科思-B(01167) 股价在下午03:34比前收市价上升6.349%,现股价为港币$1.34。至目前为止,今日最高价为$1.34,而最低价为$1.34。总成交量为5400股,总成交金额为港币$7236。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2412181502/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1574","01167"],"gpt_icon":0},{"id":"2492267927","title":"加科思-B(01167)上涨5.56%,报1.33元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492267927","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492267927?lang=zh_cn&edition=full","pubTime":"2024-12-18 14:23","pubTimestamp":1734503022,"startTime":"0","endTime":"0","summary":"12月18日,加科思-B(01167)盘中上涨5.56%,截至14:23,报1.33元/股,成交104.08万元。加科思药业集团有限公司是一家专注于临床阶段新药研发,特别是创新肿瘤疗法的自主发现和开发的中国投资控股公司。其主要药物开发项目包括JAB-3068及JAB-3312临床阶段的变构SHP2抑制剂,并主要在国内市场开展业务。截至2023年年报,加科思-B营业总收入6352.0万元、净利润-3.59亿元。8月30日,加科思-B披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/18142346529198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK1574","01167"],"gpt_icon":0},{"id":"2492194492","title":"加科思-B盘中异动 早盘大幅上涨7.14%报1.350港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492194492","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492194492?lang=zh_cn&edition=full","pubTime":"2024-12-18 10:04","pubTimestamp":1734487445,"startTime":"0","endTime":"0","summary":"2024年12月18日早盘10时04分,加科思-B股票出现波动,股价急速上涨7.14%。截至发稿,该股报1.350港元/股,成交量2.1万股,换手率0.00%,振幅0.00%。资金方面,该股资金流入0港元,流出0港元。加科思-B股票所在的生物技术行业中,整体涨幅为0.58%。其相关个股中,歌礼制药-B、圣诺医药-B、百奥赛图-B涨幅较大,振幅较大的相关个股有永泰生物-B、帝王国际投资、歌礼制药-B,振幅分别为14.23%、13.73%、12.61%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218100406a1f745d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218100406a1f745d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01167","BK1574"],"gpt_icon":0},{"id":"2491365998","title":"加科思-B12月16日主力资金流出66万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2491365998","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491365998?lang=zh_cn&edition=full","pubTime":"2024-12-16 16:15","pubTimestamp":1734336909,"startTime":"0","endTime":"0","summary":"12月16日, 加科思-B股价跌5.07%,报收1.31元,成交金额238万元,换手率0.23%,振幅12.32%,量比2.11。加科思-B今日主力资金净流出66万元,连续3日净流出,上一交易日主力净流出41万元,今日环比增加60.98%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为62.50%,平均跌幅为5.30%。该股近5个交易日下跌13.82%,主力资金累计净流出140万元;近20日主力资金累计净流出242万元,其中净流出天数为10日。该股主力净额占比0.06%,港股市场排名2583/2651。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161514ab7bc834&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161514ab7bc834&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01167","BK1161","BK1574"],"gpt_icon":0},{"id":"2491631852","title":"加科思-B(01167)下跌5.07%,报1.31元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491631852","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491631852?lang=zh_cn&edition=full","pubTime":"2024-12-16 13:32","pubTimestamp":1734327179,"startTime":"0","endTime":"0","summary":"12月16日,加科思-B(01167)盘中下跌5.07%,截至13:32,报1.31元/股,成交193.26万元。加科思药业集团有限公司是一家专注于临床阶段新药研发,特别是创新肿瘤疗法的自主发现和开发的中国投资控股公司。其主要药物开发项目包括JAB-3068及JAB-3312临床阶段的变构SHP2抑制剂,并主要在国内市场开展业务。截至2023年年报,加科思-B营业总收入6352.0万元、净利润-3.59亿元。8月30日,加科思-B披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/16133246412533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01167","BK1574"],"gpt_icon":0},{"id":"2491185686","title":"加科思-B盘中异动 早盘快速上涨6.52%报1.470港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491185686","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491185686?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:34","pubTimestamp":1734312872,"startTime":"0","endTime":"0","summary":"2024年12月16日早盘09时34分,加科思-B股票出现异动,股价大幅拉升6.52%。截至发稿,该股报1.470港元/股,成交量40.02万股,换手率0.05%,振幅0.00%。资金方面,该股资金流入1323港元,流出0港元。加科思-B股票所在的生物技术行业中,整体涨幅为0.24%。其相关个股中,云康集团、云顶新耀-B、晶泰控股-P涨幅较大,振幅较大的相关个股有创胜集团-B、晶泰控股-P、康诺亚-B,振幅分别为18.03%、5.84%、4.62%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093432ab7afb75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093432ab7afb75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01167","BK1574","BK1161"],"gpt_icon":0},{"id":"2491519343","title":"加科思-B12月13日遭主力抛售41万元 环比增加355.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491519343","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491519343?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:15","pubTimestamp":1734077735,"startTime":"0","endTime":"0","summary":"12月13日, 加科思-B股价跌3.50%,报收1.38元,成交金额244万元,换手率0.23%,振幅7.69%,量比3.13。加科思-B今日主力资金净流出41万元,上一交易日主力净流出9万元,今日环比增加355.56%。该股近5个交易日下跌6.80%,主力资金累计净流出84万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出228万元,其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161554a1eb68e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161554a1eb68e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","01167"],"gpt_icon":0},{"id":"2491391087","title":"加科思-B(01167)下跌5.59%,报1.35元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491391087","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491391087?lang=zh_cn&edition=full","pubTime":"2024-12-13 11:05","pubTimestamp":1734059148,"startTime":"0","endTime":"0","summary":"12月13日,加科思-B(01167)盘中下跌5.59%,截至11:05,报1.35元/股,成交107.99万元。加科思药业集团有限公司是一家专注于临床阶段新药研发,特别是创新肿瘤疗法的自主发现和开发的中国投资控股公司。其主要药物开发项目包括JAB-3068及JAB-3312临床阶段的变构SHP2抑制剂,并主要在国内市场开展业务。截至2023年年报,加科思-B营业总收入6352.0万元、净利润-3.59亿元。8月30日,加科思-B披露2024财年中报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/13110546348065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01167","BK1574"],"gpt_icon":0},{"id":"2491392598","title":"加科思-B盘中异动 早盘股价大跌5.59%报1.350港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491392598","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491392598?lang=zh_cn&edition=full","pubTime":"2024-12-13 11:04","pubTimestamp":1734059052,"startTime":"0","endTime":"0","summary":"2024年12月13日早盘11时04分,加科思-B股票出现异动,股价急速下挫5.59%。截至发稿,该股报1.350港元/股,成交量66.06万股,换手率0.08%,振幅5.59%。资金方面,该股资金流入17.7129万港元,流出69.903万港元。加科思-B股票所在的生物技术行业中,整体跌幅为0.80%。其相关个股中,圣诺医药-B、北海康成-B、方达控股涨幅较大,振幅较大的相关个股有晶泰控股-P、圣诺医药-B、思路迪医药股份,振幅分别为35.55%、27.53%、22.86%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213110412ab741a6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213110412ab741a6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","01167"],"gpt_icon":0},{"id":"2491839486","title":"加科思-B(01167)股价下跌5.594%,现价港币$1.35","url":"https://stock-news.laohu8.com/highlight/detail?id=2491839486","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491839486?lang=zh_cn&edition=full","pubTime":"2024-12-13 11:04","pubTimestamp":1734059040,"startTime":"0","endTime":"0","summary":"[下跌股]加科思-B(01167) 股价在上午11:04比前收市价下跌5.594%,现股价为港币$1.35。至目前为止,今日最高价为$1.43,而最低价为$1.35。总成交量为64.59万股,总成交金额为港币$88.828万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2412132183/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1161","01167"],"gpt_icon":0},{"id":"2490692060","title":"加科思-B12月10日遭主力抛售25万元 环比增加150.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490692060","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490692060?lang=zh_cn&edition=full","pubTime":"2024-12-10 16:15","pubTimestamp":1733818526,"startTime":"0","endTime":"0","summary":"12月10日, 加科思-B股价跌3.95%,报收1.46元,成交金额161万元,换手率0.14%,振幅10.53%,量比1.69。加科思-B今日主力资金净流出25万元,上一交易日主力净流出10万元,今日环比增加150.00%。该股近5个交易日下跌3.36%,主力资金累计净流出47万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出179万元,其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210161544ab6c30b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210161544ab6c30b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","01167"],"gpt_icon":0},{"id":"2490052932","title":"加科思-B(01167)下跌5.92%,报1.43元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490052932","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490052932?lang=zh_cn&edition=full","pubTime":"2024-12-10 14:06","pubTimestamp":1733810784,"startTime":"0","endTime":"0","summary":"12月10日,加科思-B(01167)盘中下跌5.92%,截至14:06,报1.43元/股,成交101.99万元。加科思药业集团有限公司是一家专注于临床阶段新药研发,特别是创新肿瘤疗法的自主发现和开发的中国投资控股公司。其主要药物开发项目包括JAB-3068及JAB-3312临床阶段的变构SHP2抑制剂,并主要在国内市场开展业务。截至2023年年报,加科思-B营业总收入6352.0万元、净利润-3.59亿元。8月30日,加科思-B披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/10140646206480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01167","BK1574","BK1161"],"gpt_icon":0},{"id":"2490052190","title":"加科思-B盘中异动 快速下跌5.26%报1.440港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490052190","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490052190?lang=zh_cn&edition=full","pubTime":"2024-12-10 14:06","pubTimestamp":1733810778,"startTime":"0","endTime":"0","summary":"2024年12月10日下午盘14时06分,加科思-B股票出现波动,股价大幅跳水5.26%。截至发稿,该股报1.440港元/股,成交量69.09万股,换手率0.09%,振幅6.58%。资金方面,该股资金流入20.0109万港元,流出74.955万港元。加科思-B股票所在的生物技术行业中,整体跌幅为1.56%。其相关个股中,思路迪医药股份、方达控股、百奥赛图-B涨幅较大,振幅较大的相关个股有思路迪医药股份、华康生物医学、来凯医药-B,振幅分别为20.54%、13.24%、11.94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210140618ab6bec00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210140618ab6bec00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","01167"],"gpt_icon":0},{"id":"2490012761","title":"加科思展示BET抑制剂初步临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2490012761","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490012761?lang=zh_cn&edition=full","pubTime":"2024-12-09 08:57","pubTimestamp":1733705842,"startTime":"0","endTime":"0","summary":"财中社12月9日电加科思-B(01167)发布公告,介绍了公司在2024年第66届美国血液学年会上展示的BET抑制剂JAB-8263治疗骨髓纤维化的初步临床数据。数据显示,JAB-8263具有良好的耐受性,二期推荐剂量为0.3毫克(每日给药)。在截至2024年10月17日的研究中,共有16名中高风险骨髓纤维化患者被纳入,其中13名患者接受了至少一次治疗后的疗效评估。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412093262288968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","01167"],"gpt_icon":0},{"id":"2490761104","title":"加科思(01167)在66届美国血液学会上展示JAB-8263治疗骨髓纤维化临床的初步数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2490761104","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490761104?lang=zh_cn&edition=full","pubTime":"2024-12-09 08:43","pubTimestamp":1733705011,"startTime":"0","endTime":"0","summary":"金吾财讯 | 加科思(01167)公布,公司在加利福尼亚州圣地牙哥举行的2024年第66届美国血液学会(“ASH”)年会上展示了BET抑制剂JAB-8263治疗骨髓纤维化(MF)临床一期的初步数据。资料显示,JAB-8263具有良好的耐受性,二期推荐剂量为0.3毫克(每日给药)。JAB-8263单药治疗骨髓纤维化适应症的初步疗效资料是令人鼓舞的。大多数患者出现脾脏缩小(spleen volume reduction,SVR)以及总症状评分(total symptom score,TSS)的降低。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/OWRlOWUwM2UzYzc0YWVmOThhNzQ1ZDFlMmFkZGIzYjY4MTQyOTUwNzU2MTA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OWRlOWUwM2UzYzc0YWVmOThhNzQ1ZDFlMmFkZGIzYjY4MTQyOTUwNzU2MTA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949180","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01167","BK1574"],"gpt_icon":0},{"id":"2490643769","title":"加科思(01167.HK)于美国展示治疗骨髓纤维化药物临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2490643769","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490643769?lang=zh_cn&edition=full","pubTime":"2024-12-09 08:09","pubTimestamp":1733702940,"startTime":"0","endTime":"0","summary":"加科思-B(01167.HK) 公布,在加利福尼亚州圣地亚哥举行的2024年第66届美国血液学会(ASH)年会上,展示了BET抑制剂“JAB-8263”治疗骨髓纤维化(MF)临床一期的初步数据。资料指,“JAB-8263”具有良好的耐受性,二期推荐剂量为0.3毫克(每日给药)。“JAB-8263”单药治疗骨髓纤维化适应症的初步疗效资料是令人鼓舞的。大多数患者出现脾脏缩小及总症状评分的降低。加科思透露,截至今年10月17日的数据,已有16名中/高风险骨髓纤维化患者被纳入研究,其中13名患者接受至少一次治疗后疗效评估。(js/w)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210503161346284_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210503161346284_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1402539/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","01167","BK1574"],"gpt_icon":0},{"id":"2490766592","title":"加科思-B(01167)在2024年第66届美国血液学会年会上展示了BET抑制剂JAB-8263 治疗骨髓纤维化(MF)临床一期的初步数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2490766592","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490766592?lang=zh_cn&edition=full","pubTime":"2024-12-09 07:55","pubTimestamp":1733702134,"startTime":"0","endTime":"0","summary":"智通财经APP讯,加科思-B(01167)发布公告,公司在加利福尼亚州圣地牙哥举行的2024年第66届美国血液学会(ASH)年会上展示了BET抑制剂JAB-8263 治疗骨髓纤维化(MF)临床一期的初步数据。资料显示,JAB-8263具有良好的耐受性,二期推荐剂量为0.3毫克(每日给药)。 JAB-8263单药治疗骨髓纤维化适应症的初步疗效资料是令人鼓舞的。大多数患者出现脾脏缩小(spleen volume reduction, SVR)以及总症状评分(total symptom score,TSS)的降低。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221901.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01167","MF","BK1574","BK4526","BK4539","BK1161","BK4563","BK4113"],"gpt_icon":0},{"id":"2489212421","title":"加科思-B盘中异动 股价大涨5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489212421","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489212421?lang=zh_cn&edition=full","pubTime":"2024-12-06 11:44","pubTimestamp":1733456668,"startTime":"0","endTime":"0","summary":"2024年12月06日临近午盘11时44分,加科思-B股票出现波动,股价快速拉升5.59%。截至发稿,该股报1.510港元/股,成交量31.47万股,换手率0.04%,振幅5.59%。资金方面,该股资金流入34.9863万港元,流出10.5903万港元。加科思-B股票所在的生物技术行业中,整体涨幅为2.03%。其相关个股中,北海康成-B、云康集团、巨子生物涨幅较大,振幅较大的相关个股有北海康成-B、来凯医药-B、永泰生物-B,振幅分别为50.00%、13.75%、13.30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206114428a1d818f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206114428a1d818f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01167","BK1161"],"gpt_icon":0},{"id":"2487377203","title":"加科思-B(01167)下跌5.16%,报1.47元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2487377203","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487377203?lang=zh_cn&edition=full","pubTime":"2024-11-29 10:38","pubTimestamp":1732847894,"startTime":"0","endTime":"0","summary":"11月29日,加科思-B(01167)盘中下跌5.16%,截至10:38,报1.47元/股,成交109.42万元。加科思药业集团有限公司是一家专注于临床阶段新药研发,特别是创新肿瘤疗法的自主发现和开发的中国投资控股公司。其主要药物开发项目包括JAB-3068及JAB-3312临床阶段的变构SHP2抑制剂,并主要在国内市场开展业务。截至2023年年报,加科思-B营业总收入6352.0万元、净利润-3.59亿元。8月30日,加科思-B披露2024财年中报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/29103845826628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01167","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jacobiopharma.com","stockEarnings":[{"period":"1week","weight":-0.0629},{"period":"1month","weight":-0.2071},{"period":"3month","weight":-0.2343},{"period":"6month","weight":-0.1779},{"period":"1year","weight":-0.6309},{"period":"ytd","weight":-0.6298}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"加科思药业集团有限公司是一家主要从事临床阶段新药研发的中国投资控股公司。该公司主要负责创新肿瘤疗法的自主发现和开发。公司主要药物开发项目包括JAB-3068及JAB-3312临床阶段的变构SHP2抑制剂。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.005532},{"month":2,"riseRate":0.25,"avgChangeRate":0.053851},{"month":3,"riseRate":0,"avgChangeRate":-0.187604},{"month":4,"riseRate":0.75,"avgChangeRate":0.048427},{"month":5,"riseRate":0.25,"avgChangeRate":-0.044098},{"month":6,"riseRate":0,"avgChangeRate":-0.038854},{"month":7,"riseRate":0.25,"avgChangeRate":-0.142126},{"month":8,"riseRate":0.25,"avgChangeRate":0.016101},{"month":9,"riseRate":0.5,"avgChangeRate":-0.057977},{"month":10,"riseRate":0.25,"avgChangeRate":-0.01812},{"month":11,"riseRate":0.25,"avgChangeRate":0.006165},{"month":12,"riseRate":0.25,"avgChangeRate":-0.023367}],"exchange":"SEHK","name":"加科思-B","nameEN":"JACOBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"加科思-B(01167)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供加科思-B(01167)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"加科思-B,01167,加科思-B股票,加科思-B股票老虎,加科思-B股票老虎国际,加科思-B行情,加科思-B股票行情,加科思-B股价,加科思-B股市,加科思-B股票价格,加科思-B股票交易,加科思-B股票购买,加科思-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"加科思-B(01167)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供加科思-B(01167)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}